Ketone Supplement for Colorectal Cancer Prevention
(BHB-CRC Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores whether a ketone supplement, specifically beta-hydroxybutyrate (BHB), can help prevent colorectal cancer. Participants will take a liquid form of this supplement, called R-1,3-Butanediol, three times a day for four weeks. The trial targets individuals already scheduled for a colonoscopy or flexible sigmoidoscopy, standard procedures for checking colon health. Suitable candidates should not have certain medical conditions, such as diabetes or chronic kidney disease, and should not follow special diets like the ketogenic diet or intermittent fasting. As an unphased trial, this study offers a unique opportunity to contribute to groundbreaking research on cancer prevention.
Do I need to stop my current medications for this trial?
The trial information does not specify if you need to stop taking your current medications. However, if you have diabetes and are on diabetes medication, you cannot participate in this trial.
What prior data suggests that beta-hydroxybutyrate supplementation is safe?
Research has shown that R-1,3-Butanediol, an ingredient in the ketone supplement under testing, is generally safe for people. Studies indicate it can quickly increase levels of beta-hydroxybutyrate (BHB) in the blood. BHB is a type of ketone produced when fewer carbohydrates are consumed.
In studies where participants took R-1,3-Butanediol, no serious side effects occurred. Some individuals might experience mild stomach discomfort, but many find it manageable. This information is promising for those considering participation in a clinical trial with this supplement.12345Why are researchers excited about this trial?
Unlike the standard treatments for colorectal cancer, which often involve surgery, chemotherapy, and radiation, the new approach with R-1,3-Butanediol focuses on prevention. This treatment is unique because it uses a ketone supplement, HVMN Ketone-IQ, which introduces R-1,3-Butanediol into the body. Researchers are excited about this because ketones provide an alternative energy source for cells, potentially reducing the growth of cancerous cells by limiting their access to glucose. This novel method could offer a non-invasive preventive strategy, setting it apart from more aggressive traditional treatments.
What evidence suggests that this treatment might be an effective treatment for colorectal cancer prevention?
Research has shown that beta-hydroxybutyrate (BHB), administered in this trial as R-1,3-Butanediol, might lower the risk of colorectal cancer. One study found that BHB treatment alone reduced the number of tumors in the colon. Additionally, BHB slowed the growth of colon cancer cells. Another study suggested that BHB can also slow the spread of abnormal cells in the colon. These findings support the potential of BHB in preventing colorectal cancer.56789
Who Is on the Research Team?
Bryson W Katona, MD, PhD
Principal Investigator
University of Pennsylvania
Are You a Good Fit for This Trial?
This trial is for adults over 18 who can consent and are scheduled for a standard colonoscopy or flexible sigmoidoscopy. It's not suitable for those with diabetes on medication, severe kidney disease, active cancer treatment, pregnancy, incarceration, under 18s, history of bowel diseases or recent fasting diets.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive BHB supplementation through oral administration of HVMN Ketone-IQ for 4 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- R-1,3-Butanediol
Find a Clinic Near You
Who Is Running the Clinical Trial?
Abramson Cancer Center of the University of Pennsylvania
Lead Sponsor
Abramson Cancer Center at Penn Medicine
Lead Sponsor